Breaking News

Moderna Resolves Worldwide Arbutus/Genevant Litigation

Settles the long-running legal fight over the technology that made its COVID-19 vaccine possible.

Author Image

By: Charlie Sternberg

Associate Editor

Moderna Inc. has entered into a settlement agreement resolving all worldwide Arbutus Biopharma Corporation/Genevant Sciences GmbH litigation related to Spikevax and mRESVIA. The agreement also provides certainty going forward for Moderna’s full infectious disease portfolio, including mNEXSPIKE, mCOMBRIAX and its future vaccine pipeline, with no future royalties owed. Under the terms of the agreement, Moderna will make a lump sum payment of $950 million in the third quarter of 2026. Unde...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters